Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director | July 31, 2026 | August 04, 2026 |
| Scribe Therapeutics, Inc.SCTX · Entity 5494 | Chief Business Officer | March 13, 2026 | July 28, 2026 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jasper Therapeutics, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2036-07-31 | Direct | 7,500 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 7,500 · Balance 7,500 F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Scribe Therapeutics, Inc.
Report date March 13, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 3,000 |
Reported balance
After 2026-07-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-23 · Purchase · Acquired 3,000 · Balance 3,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2036-03-12 | Direct | 9,547 |
Reported balance
After 2026-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-13 · Grant · Acquired 9,547 · Balance 9,547 F1: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a). F2: The option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-07-22 | Direct | 109,426 |
Reported balance
After 2026-07-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-23 · Grant · Acquired 109,426 · Balance 109,426 F3: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Performance-based Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-07-22 | Direct | 109,426 |
Reported balance
After 2026-07-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-23 · Grant · Acquired 109,426 · Balance 109,426 F4: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
F2: The option is fully vested.
F3: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
aTYR PHARMA INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-11 | Direct | 50,000 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 50,000 · Balance 50,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 20:10 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (Right to Buy · Derivative | 7,500 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001213900-26-085191 · ownership.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2036-07-31 F1 · derivative.exercise_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. F1 · derivative.expiration_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. Read SEC document |
| July 23, 2026 Filed Jul 28, 2026 01:42 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | GrantPerformance-based Stock Option (Right to Buy) · Derivative | 109,426 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001781292-26-000007 · form4-07282026_010709.xml · derivative · entry 4 Lucas Svetlana · CIK 0001781292 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,426 Underlying: Common Stock · 109,426 shares Expires 2036-07-22 F4 · derivative.exercise_date: The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 23, 2026 Filed Jul 28, 2026 01:42 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | GrantStock Option (Right to Buy) · Derivative | 109,426 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001781292-26-000007 · form4-07282026_010709.xml · derivative · entry 3 Lucas Svetlana · CIK 0001781292 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,426 Underlying: Common Stock · 109,426 shares Expires 2036-07-22 F3 · derivative.exercise_date: The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 23, 2026 Filed Jul 28, 2026 01:42 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | PurchaseCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001781292-26-000007 · form4-07282026_010709.xml · nonDerivative · entry 1 Lucas Svetlana · CIK 0001781292 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 3,000 Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:12 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001781292-26-000003 · ownership.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-05-11 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| March 13, 2026 Filed Jul 28, 2026 01:42 UTC | Scribe Therapeutics, Inc. SCTX · Entity 5494 | GrantStock Option (Right to Buy) · Derivative | 9,547 | $0.00 Strike: $19.13 | $0.00 |
DisclosureSEC source: 0001781292-26-000007 · form4-07282026_010709.xml · derivative · entry 2 Lucas Svetlana · CIK 0001781292 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,547 Underlying: Common Stock · 9,547 shares Expires 2036-03-12 F1 · date: The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a). F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 20,000 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0001213900-25-091104 · ownership.xml · derivative · entry 2 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Voting Common Stock · 20,000 shares Expires 2030-03-22 F1 · price: Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:01 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | PurchaseVoting Common Stock | 20,000 | $2.43 | $48,600.00 |
DisclosureSEC source: 0001213900-25-091104 · ownership.xml · nonDerivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant. Read SEC document |
| July 03, 2025 Filed Jul 3, 2025 20:20 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001213900-25-061492 · ownership.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2035-07-03 F1 · shares: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 2, 2025 21:22 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0000950170-25-062942 · ownership.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-01 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 10:07 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.19 | $0.00 |
DisclosureSEC source: 0001213900-24-053989 · ownership.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Voting Common Stock · 15,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on June 18, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:19 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0000950170-24-064225 · ownership.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 22, 2025 or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:30 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-23-031016 · doc4.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 17, 2024 or (ii) the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:53 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026065 · doc4.xml · derivative · entry 2 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs fully vested one year from the grant date which was April 26, 2022. F3 · derivative.expiration_date: The RSUs fully vested one year from the grant date which was April 26, 2022. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:53 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026065 · doc4.xml · nonDerivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022. F2 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 23:50 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026091 · doc4.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. F2 · derivative.expiration_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 00:11 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-21-029123 · doc4.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2031-04-28 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) April 28, 2022 or (ii) the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:08 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-20-027984 · doc4.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2030-05-06 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 21:16 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 2,285 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-19-040458 · doc4.xml · derivative · entry 1 Lucas Svetlana · CIK 0001781292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,285 Underlying: Common Stock · 2,285 shares Expires 2029-06-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning July 28, 2019, such that this option will be fully exercisable on June 28, 2022, subject to the recipient's continued service on the Issuer's Board of Directors. F2 · derivative.underlying_shares: The shares of Common Stock reported herein give effect to the 1-for-14 reverse stock split which became effective in accordance with the terms of the Certificate of Amendment to the Company's Restated Certificate of Incorporation filed with the Secretary of State of Delaware on June 28, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.